• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PALBOCICLIB Drug Record

  • Summary
  • Interactions
  • Claims
  • PALBOCICLIB chembl:CHEMBL189963 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    PD-0332991
    PALBOCICLIB
    IBRANCE
    UNII-G9ZF61LE7G
    PD 332991
    IBRANCE®
    6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-{[5-(PIPERAZIN-1-YL)PYRIDIN-2-YL]AMINO}PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
    PD 0332991
    PD0332991
    6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE
    rxcui:1601374
    chemidplus:571190-30-2
    chembl:CHEMBL189963
    pubchem.compound:5330286
    drugbank:09073

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval Breast cancer (HR+, HER2-)
    Drug Class Small molecule inhibitor
    Pharmaceutical Developer Pfizer
    Source Reported Drug Name(s) PD0332991
    Drug Class CDK/Rb Inhibitor
    (9 More Sources)

    Publications:

    Fry et al., 2004, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts., Mol. Cancer Ther.
    Rocca A et al., 2017, Progress with palbociclib in breast cancer: latest evidence and clinical considerations., Ther Adv Med Oncol
    Finn et al., 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study., Lancet Oncol.
    Gao et al., 2015, Does CDKN2A loss predict palbociclib benefit?, Curr Oncol
    Konecny et al., 2011, Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer., Clin. Cancer Res.
    Young et al., 2014, Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines., Pigment Cell Melanoma Res
    Logan et al., 2013, PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity., Anticancer Res.
    Cen et al., 2012, p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells., Neuro-oncology
    Forbes et al., 2011, COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer., Nucleic Acids Res.
    Huang et al., 2015, CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation., Int J Clin Exp Med
    Katsumi et al., 2011, Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression., Biochem. Biophys. Res. Commun.
    Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.
    von Witzleben et al., 2015, Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway., Cancer Res.
    Kwong et al., 2012, Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma., Nat. Med.
    Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget
    Perez et al., 2015, Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA., Oncotarget
    Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol
    Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem
    Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
    Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
    Ziemke et al., 2016, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6., Clin. Cancer Res.
    Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
    Witkiewicz et al., 2014, CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models., Genes Cancer
    Finn et al., 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro., Breast Cancer Res.
    Uras et al., 2016, Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6., Blood
    Taylor-Harding B et al., 2015, Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS., Oncotarget
    Turner NC et al., 2019, Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer., J Clin Oncol
    Hanaford et al., 2016, DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets., Clin. Cancer Res.
    Schröder et al., 2015, CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?, Front Oncol
    Michaud et al., 2010, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts., Cancer Res.
    Dean et al., 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure., Oncogene
    Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol
    Sawai et al., 2012, Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia., Cancer Cell
    Lee et al., 2016, Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models., Oncotarget
    Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
    Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
  • PALBOCICLIB   CDKN2B

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23898052


    Sources:
    CIViC

  • PALBOCICLIB   CCNE1

    Interaction Score: 1.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27020857 25557169 30807234


    Sources:
    CIViC

  • PALBOCICLIB   CDKN2A

    Interaction Score: 1.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Trametinib
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    26715889 21278246 24495407 23898052 22711607 20952405 26380006 21871868 27488531 26183925 22983396 25156567 26528855


    Sources:
    JAX-CKB CIViC OncoKB

  • PALBOCICLIB   CCND3

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23079656


    Sources:
    CIViC

  • PALBOCICLIB   CDK4

    Interaction Score: 0.7

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction CDK4/cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    27124835 23569312 26528855 15542782 24417566 23898052 25810375 28203301


    Sources:
    DTC MyCancerGenome ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • PALBOCICLIB   RB1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type resistant
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27012813 26649278 27020857 27488531 22711607 20354191 20473330 29236940


    Sources:
    JAX-CKB CIViC

  • PALBOCICLIB   SMARCA4

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718506 30718512


    Sources:
    CIViC

  • PALBOCICLIB   CDK6

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction CDK6/cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    15542782 28203301


    Sources:
    MyCancerGenome ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

  • PALBOCICLIB   SMARCB1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type rhabdoid cancer
    Response Type decreased response
    Approval Status Preclinical

    PMIDs:
    21871868


    Sources:
    JAX-CKB

  • PALBOCICLIB   CCND1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction CDK6/cyclin D1 inhibitor
    Direct Interaction yes

    PMIDs:
    24417566


    Sources:
    DTC ChemblInteractions

  • PALBOCICLIB   DYRK1B

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   PRKX

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   NEK2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   NRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    22983396 27488531


    Sources:
    JAX-CKB

  • PALBOCICLIB   DAPK3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   PAK4

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   DYRK1A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   CDK9

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    26369631 27167191 1291017 26658964


    Sources:
    JAX-CKB CIViC

  • PALBOCICLIB   CLK2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MST1R

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   LRRK2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   ERBB2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Trastuzumab
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type sensitive

    PMIDs:
    25221644 27020857 19874578


    Sources:
    JAX-CKB PharmGKB FDA

  • PALBOCICLIB   PRKAA1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MAP4K2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   PIK3CA

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Her2-receptor positive breast cancer
    Response Type no benefit
    Approval Status Preclinical

    PMIDs:
    27020857 26369631 25002028


    Sources:
    JAX-CKB CIViC

  • PALBOCICLIB   TAOK1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MAPK9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MAP4K5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   BRAF

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26369631 27488531


    Sources:
    JAX-CKB

  • PALBOCICLIB   CHEK1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   RPS6KA3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   ROCK2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   PRKD3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MAP4K4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MAPK8

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   CDK5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   FLT3

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Tandutinib
    combination therapy Palbociclib + SGI-1776
    combination therapy Palbociclib + Quizartinib

    PMIDs:
    27099147


    Sources:
    JAX-CKB

  • PALBOCICLIB   PTEN

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + GDC-0941
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type no benefit

    PMIDs:
    27020857


    Sources:
    JAX-CKB

  • PALBOCICLIB   ESR1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25524798


    Sources:
    CIViC PharmGKB FDA

  • PALBOCICLIB   CLK4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   PGR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PALBOCICLIB   ALK

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   ESR2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PALBOCICLIB   RET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: PALBOCICLIB

    • Version: 20-Jun-2017

    Alternate Names:
    IBRANCE Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Breast cancer (HR+, HER2-)

    Publications:

  • CancerCommons: PALBOCICLIB

    • Version: 25-July-2013

    Alternate Names:
    PD 0332991 PubChem Drug Name
    11431660 PubChem Drug ID
    Palbociclib Drug Trade Name

    Drug Info:
    Drug Class CDK/Rb Inhibitor
    Source Reported Drug Name(s) PD0332991
    Pharmaceutical Developer Pfizer

    Publications:

  • MyCancerGenome: PD0332991

    • Version: 20-Jun-2017

    Alternate Names:
    PD0332991 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • DTC: PALBOCICLIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL189963 ChEMBL Drug ID

    Drug Info:

    Publications:
    Reddy MV et al., 2014, Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5)., J Med Chem

  • JAX-CKB: Palbociclib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
    Ziemke et al., 2016, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6., Clin. Cancer Res.
    Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.

  • JAX-CKB: PD0332991

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Franco et al., 2014, CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer., Oncotarget

  • CIViC: PALBOCICLIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Olanich ME et al., 2015, CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma., Clin Cancer Res
    Dickson et al., 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma., J. Clin. Oncol.
    Dickson et al., 2016, Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial., JAMA Oncol

  • ChemblDrugs: chembl:CHEMBL189963

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: PD-0332991

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Palbociclib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: palbociclib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL189963

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Palbociclib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21